losartan has been researched along with Bone Cancer in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan inhibits the CCL2-CCR2 axis, and in combination with toceranib, exerts significant biological activity in dogs with metastatic osteosarcoma, supporting evaluation of this drug combination in patients with pediatric osteosarcoma." | 8.12 | Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. ( Chow, L; Coy, JW; Das, S; Dow, SW; Gustafson, DL; Haines, L; Kurihara, JN; Mathias, A; Palmer, E; Regan, DP; Thamm, DH, 2022) |
| "Losartan inhibits the CCL2-CCR2 axis, and in combination with toceranib, exerts significant biological activity in dogs with metastatic osteosarcoma, supporting evaluation of this drug combination in patients with pediatric osteosarcoma." | 4.12 | Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. ( Chow, L; Coy, JW; Das, S; Dow, SW; Gustafson, DL; Haines, L; Kurihara, JN; Mathias, A; Palmer, E; Regan, DP; Thamm, DH, 2022) |
| " Spontaneous and evoked pain behaviors were assessed before and after acute and chronic administration of Ang-(1-7)." | 1.43 | Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. ( Arnold, MR; Forte, BL; Hay, M; Largent-Milnes, TM; Slosky, LM; Staatz, WD; Vanderah, TW; Zhang, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Regan, DP | 1 |
| Chow, L | 1 |
| Das, S | 1 |
| Haines, L | 1 |
| Palmer, E | 1 |
| Kurihara, JN | 1 |
| Coy, JW | 1 |
| Mathias, A | 1 |
| Thamm, DH | 1 |
| Gustafson, DL | 1 |
| Dow, SW | 1 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Forte, BL | 1 |
| Slosky, LM | 1 |
| Zhang, H | 1 |
| Arnold, MR | 1 |
| Staatz, WD | 1 |
| Hay, M | 1 |
| Largent-Milnes, TM | 1 |
| Vanderah, TW | 1 |
3 other studies available for losartan and Bone Cancer
| Article | Year |
|---|---|
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Humans; Leukocytes, Mononuclear; Losartan; Mice; Monocy | 2022 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.
Topics: Analgesics; Analysis of Variance; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensi | 2016 |